Skip to main content
. Author manuscript; available in PMC: 2019 Jul 11.
Published in final edited form as: Cell Host Microbe. 2018 Jun 21;24(1):97–108.e4. doi: 10.1016/j.chom.2018.05.009

Fig. 4. GPX4 blocks GSDMD cleavage during inflammasome activation.

Fig. 4

(A) Western blot analysis of IL-1β and caspase-11 protein expression in BMDMs following treatment with LPS (500 ng/ml), poly (I:C) (5 μg/ml), Pam3CSK4 (1 μg/ml), or IFN-γ (10/ng/ml) for six hours. (B) Q-PCR analysis of IL-1β and caspase-11 mRNA expression in BMDMs following treatment with LPS (500 ng/ml), poly (I:C) (5 μg/ml), Pam3CSK4 (1 μg/ml), or IFN-γ (10/ng/ml) for six hours. (C) Western blot analysis of indicated proteins in BMDMs recovered from mice with the indicated genotypes following LPS electroporation or E. coli (MOI=25) infection for 16 hours. Sup= supernatants. (D) In parallel, cytotoxicity (LDH release) and levels of IL-1β and HMGB1 in the supernatant were assayed (n=3 wells/group; data expressed as means ± SD, *, P<0.05, ANOVA LSD test). (E) Western blot analysis of LPS (500 ng/ml)-primed indicated BMDMs following treatment with ATP (5 mM) for one hour. Sup=supernatants. (F) In parallel, cytotoxicity and levels of IL-1β and HMGB1 in the supernatant were assayed (n=3 wells/group; data expressed as means ± SD, *, P<0.05, ANOVA LSD test).